'Iu ml' presentation slideshows

1.1k views • 62 slides

Hong Kong Association of Blood Transfusion & Haematology NAT and Viral Safety in Blood Transfusion

Hong Kong Association of Blood Transfusion & Haematology NAT and Viral Safety in Blood Transfusion Dr. P.H. Yu Medical Officer Department of Pathology Tseung Kwan O Hospital Viral Safety in Blood Transfusion

1.72k views • 58 slides

Hong Kong Association of Blood Transfusion & Haematology NAT and Viral Safety in Blood Transfusion

Hong Kong Association of Blood Transfusion & Haematology NAT and Viral Safety in Blood Transfusion. Dr. P.H. Yu Medical Officer Department of Pathology Tseung Kwan O Hospital. Viral Safety in Blood Transfusion.

810 views • 58 slides

Ovarian Cancer

Ovarian Cancer. Tim Broadhead Consultant Gynaecologist & Gynaecological Oncologist. Ovarian Cancer. Introduction Pathology Aetiology Staging Symptoms & Examination Tests Treatment Future Developments. Introduction. 6700 cases in UK each year 5 th commonest cancer in women

838 views • 50 slides

1.44k views • 50 slides

Use of Boceprevir ( Victrelis ) in the Treatment of Chronic Hepatitis C Virus

Use of Boceprevir ( Victrelis ) in the Treatment of Chronic Hepatitis C Virus. Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: July 26 , 2011. HEPATITIS C: TREATMENT. Boceprevir ( Victrelis ). Background and Dosing. HEPATITIS C: TREATMENT.

644 views • 45 slides

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice

Strategic Applications of HCV Guidelines: Putting Protease Inhibitors into Practice. Jeff Allen, MD, FAAFP Chief of Health Programs, FBOP Michelle Williams, PharmD Lieutenant, USPHS Hepatitis/HIV Program Manager, FBOP Newton Kendig , MD RADM, Assistant Surgeon General, USPHS

510 views • 34 slides

Case finding for HBV in the UK

Case finding for HBV in the UK. Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. 350 million HBV-infected individuals worldwide 15-40% will develop serious complications related to cHBV

498 views • 33 slides

Evaluation and Management of Nonobstructive Azoospermia

1.08k views • 31 slides

Chronic Hepatitis B Evaluation and Management

962 views • 24 slides

Figure:

Figure:

280 views • 19 slides

Disclosure Information

299 views • 18 slides

NAT Proficiency Study Program in Japan

NAT Proficiency Study Program in Japan . Saeko Mizusawa, Yoshiaki Okada National Institute of Infectious Diseases, Japan. SoGAT XXI In Brussels, Belgium 28-29 May 2009. Background. National Standards for NAT Calibrated against WHO IS HCV(1999 ), HBV(2002 ), HIV(2002).

290 views • 17 slides

Serological investigation of bat rabies in Southern China

Serological investigation of bat rabies in Southern China. Changchun Tu. Diagnostic Laboratory on Rabies and Wildlife Associated Zoonoses, Ministry of Agriculture of China. Rabies Transmission Cycle. rabid domestic animal. rabid wild animal. Exposed human. Intermediate host.

412 views • 17 slides

Distributions of parvovirus B19 genotype 1-3 in blood donations

Distributions of parvovirus B19 genotype 1-3 in blood donations. MHGM Koppelman and HTM Cuijpers. Specificity of commercial test kits for Parvo B19 virus genotype 2 and 3.

671 views • 12 slides

Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd.

371 views • 10 slides

Sofosbuvir + Ribavirin in HCV Genotype 1 NIH SPARE

234 views • 9 slides

Sofosbuvir in Genotype 2 or 3 FUSION Trial

Phase 3. Treatment Experienced. Sofosbuvir in Genotype 2 or 3 FUSION Trial. *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3 Unable to receive PEG). Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

185 views • 9 slides

Future Trials of Hepatitis C Therapy in the HIV Co-infected

Future Trials of Hepatitis C Therapy in the HIV Co-infected. Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases University of Alberta. Ongoing Clinical Trials of HCV Therapy in the HIV Co-infected.

174 views • 9 slides

CASE 2

CASE 2 . 32 yo woman born in China HBsAg + HBeAg + anti-HCV- anti-HIV- ALT 19 AST 18 Bili 9 Plts 266 Albumin 41 INR 1.0. CASE 2 . Fibrotest / Fibroscan minimal scarring HBV DNA 2.66 x 10 9 IU/ mL What stage of CHB is she in? Would you treat?. CASE 2 .

168 views • 3 slides